Research Progress and Application of Daratumumab in Non-Multiple Myeloma--Review.
10.19746/j.cnki.issn.1009-2137.2023.05.051
- Author:
Fan GAO
1
,
2
,
3
;
Fei LI
1
,
2
,
4
Author Information
1. Department of Hematology, The First Affiliated Hospital of Nanchang University
2. Institute of Hematology, Academy of Clinical Medicine of Jiangxi Province
3. Institute of Lymphoma of Nanchang University, Nanchang 330006, Jiangxi Province, China.
4. Institute of Lymphoma of Nanchang University, Nanchang 330006, Jiangxi Province, China.E-mail: yx021021@sina.com.
- Publication Type:Journal Article
- Keywords:
clinical application;
daratumumab;
non-multiple myeloma;
reserach progress
- MeSH:
Humans;
Multiple Myeloma/pathology*;
ADP-ribosyl Cyclase 1;
Antibodies, Monoclonal/pharmacology*;
Hematologic Neoplasms/drug therapy*
- From:
Journal of Experimental Hematology
2023;31(5):1574-1578
- CountryChina
- Language:Chinese
-
Abstract:
Daratumumab is the first CD38 monoclonal antibody drug approved for the treatment of patients with multiple myeloma. It can bind to CD38 expressed by tumor cells, inhibit tumor cell growth and induce myeloma cell apoptosis through a variety of immune-related mechanisms. Meanwhile, CD38 is also expressed in other cells, including regulatory T cells, regulatory B cells and myeloid-derived suppressor cells, which provides a theoretical basis for the treatment of hematological tumor diseases other than non-multiple myeloma diseases. This article reviews the research progress and application of this part.
